Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (258 reviews)

For research use only. Not for use in humans.

Catalog No.S1009 Synonyms: NVP-BEZ235

258 publications

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.

Selleck's Dactolisib (BEZ235) has been cited by 258 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 514(7524):628-32

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 487(7408):505-9

PubMed: 22763448 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )
Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )
Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )
Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )
Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )
Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )
BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )
J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )
Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )
Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MW\BcpRqdWmlcn;ibYFtKEG\|c3H5		NGrUSnMyQCCq	NUfOemZmTE2VTx?=	NFnlbHZCdnSrdIL5dIFvd3OxbXHsJIFkfGm4aYT5JJdqfGhiRVO1NEBw\iByLkCwNlUh\|ryP	NH75O3AzPDhyNUm0Oi=>
MCF7	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXKwMlAyNTFyMDFOwG0>	MmrMOFghcA>?	MYDEUXNQ	M{iyXWlEPTB;MD63N{DPxE1?	MVKyN\|g4OTlyNB?=
HCT116	NXrvR4tIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HVTFAvODFvMUCwJO69VQ>?	NUHHTGVPPDhiaB?=	MlrZSG1UVw>?	NWPVU5dvUUN3ME2xMlE3KM7:TR?=	NFHIUYYzOzh5MUmwOC=>
U87MG	M{j1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTFT3poOC5yMT2xNFAh\|ryP	NFLFepk1QCCq	NFfXZmVFVVOR	NXHFRnczUUN3ME2xMlMzKM7:TR?=	NXnydpdCOjN6N{G5NFQ>
HBC4	NUTjNYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rFXlAvODFvMUCwJO69VQ>?	MlXlOFghcA>?		NIDQd2pNd2diR1m1NF0uQC54MTDN	NEjYW2UzOjN\|NkK0Oi=>
BSY1	M4nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrvZoZYOC5yMT2xNFAh\|ryP	NGixS\|E1QCCq		Ml72UI9oKEeLNUC9MVgvPDhiTR?=	NGHTN4ozOjN\|NkK0Oi=>
HBC5	M3zObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFmwZoQxNjBzLUGwNEDPxE1?	MmTqOFghcA>?		NIPYTFRNd2diR1m1NF0uPy56NzDN	M{DyflIzOzN4MkS2
MCF7	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrsN413OC5yMT2xNFAh\|ryP	NXTZc3pvPDhiaB?=		NFvPbmlNd2diR1m1NF0uQC5zNjDN	Mmi4NlI{OzZ{NE[=
MDA-MB-231	NW\vNXdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVWwMlAyNTFyMDFOwG0>	NVfJOIk5PDhiaB?=		NIPTNVVNd2diR1m1NF0uQC5yOTDN	M{PoVFIzOzN4MkS2
U251	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfq[pAxNjBzLUGwNEDPxE1?	M2jMVlQ5KGh?		M2\mZ2xw\yCJSUWwQU04NjZ4IF2=	NFTmS2YzOjN\|NkK0Oi=>
SF268	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfFNE4xOS1zMECg{txO	MXK0PEBp		Mn\oUI9oKEeLNUC9MVcvQTJiTR?=	NUHuNY1tOjJ\|M{[yOFY>
SF295	M4P1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH0d2gxNjBzLUGwNEDPxE1?	M3;xWVQ5KGh?		M{n5cmxw\yCJSUWwQU05NjNzIF2=	M{LKXVIzOzN4MkS2
SF539	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DKZ\|AvODFvMUCwJO69VQ>?	MnfLOFghcA>?		M{TCc2xw\yCJSUWwQU05NjV7IF2=	NXr5VXZjOjJ\|M{[yOFY>
SNB75	MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3uNE4xOS1zMECg{txO	NEL1PVk1QCCq		NYCz[2l2VG:pIFfJOVA:NThwNUigUS=>	M2r3R\|IzOzN4MkS2
SNB78	NHq5fWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13pfVAvODFvMUCwJO69VQ>?	NUTGfWxTPDhiaB?=		MXzMc4chT0l3ME2tPE43PSCP	NGXzXlAzOjN\|NkK0Oi=>
HCC2998	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXewMlAyNTFyMDFOwG0>	NGLOWHg1QCCq		NFPNUodNd2diR1m1NF0uQC5yNTDN	MV:yNlM{PjJ2Nh?=
KM12	M{DEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXywMlAyNTFyMDFOwG0>	NFiyPIk1QCCq		NXPoPZFQVG:pIFfJOVA:NTdwNUSgUS=>	MYmyNlM{PjJ2Nh?=
HT-29	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXENE4xOS1zMECg{txO	Mkf3OFghcA>?		MUHMc4chT0l3ME2tO{44PSCP	NXj1foZyOjJ\|M{[yOFY>
HCT15	M2\wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M130clAvODFvMUCwJO69VQ>?	MX20PEBp		MWDMc4chT0l3ME2tPE4xOyCP	MVeyNlM{PjJ2Nh?=
HCT116	NUXxSIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLCNE4xOS1zMECg{txO	Mo\ROFghcA>?		MVLMc4chT0l3ME2tO{43OSCP	M2XueFIzOzN4MkS2
NCI-H23	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\y[FNoOC5yMT2xNFAh\|ryP	NWP3[nVmPDhiaB?=		NW\GfFFbVG:pIFfJOVA:NTdwNkSgUS=>	M{PCd\|IzOzN4MkS2
NCI-H226	NFfFR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjONE4xOS1zMECg{txO	M2jBTlQ5KGh?		NWTacHdRVG:pIFfJOVA:NThwNESgUS=>	MkfrNlI{OzZ{NE[=
NCI-H522	M4nxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrDNE4xOS1zMECg{txO	M2TQW\|Q5KGh?		NFzCTVFNd2diR1m1NF0uQC52NTDN	NFPOSIszOjN\|NkK0Oi=>
NCI-H438	NHrBOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWwMlAyNTFyMDFOwG0>	NU\XU5k4PDhiaB?=		NULYelc1VG:pIFfJOVA:NThwMUGgUS=>	MVqyNlM{PjJ2Nh?=
A549	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HId\|AvODFvMUCwJO69VQ>?	NULUXGtxPDhiaB?=		NF62S3RNd2diR1m1NF0uQC5yNzDN	NYX0fZRIOjJ\|M{[yOFY>
DMS273	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWOwMlAyNTFyMDFOwG0>	NEfQcZY1QCCq		MkPHUI9oKEeLNUC9MVcvQDBiTR?=	NYDPOXd7OjJ\|M{[yOFY>
DMS114	NWjZPHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLwbGpLOC5yMT2xNFAh\|ryP	NVO3d\|cyPDhiaB?=		NWrKSYJCVG:pIFfJOVA:NThwM{mgUS=>	NXXUSHhkOjJ\|M{[yOFY>
LOXIMVI	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHVTJExNjBzLUGwNEDPxE1?	NGPKdoE1QCCq		NE\rUppNd2diR1m1NF0uQC54NjDN	NEP1fIIzOjN\|NkK0Oi=>
OVCAR3	NYHLXJpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3f5dFAvODFvMUCwJO69VQ>?	M{\KWlQ5KGh?		MUjMc4chT0l3ME2tPE4yPyCP	MYeyNlM{PjJ2Nh?=
OVCAR4	M2D0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Hh[lAvODFvMUCwJO69VQ>?	NV7LNY0yPDhiaB?=		NELBe4xNd2diR1m1NF0uQC53ODDN	M4W0WVIzOzN4MkS2
OVCAR5	M4PZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTQNE4xOS1zMECg{txO	NUf6fVkzPDhiaB?=		MmXTUI9oKEeLNUC9MVcvPTdiTR?=	Mn;pNlI{OzZ{NE[=
OVCAR8	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXaNE4xOS1zMECg{txO	NWL6TmJxPDhiaB?=		NGjHUJBNd2diR1m1NF0uPy56NDDN	MXmyNlM{PjJ2Nh?=
SKOV3	NV6zTHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M132T\|AvODFvMUCwJO69VQ>?	MUW0PEBp		NXqwRY5[VG:pIFfJOVA:NThwNEGgUS=>	NY\pV4ExOjJ\|M{[yOFY>
RXF631L	NF6xR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPJZ3YxNjBzLUGwNEDPxE1?	MorjOFghcA>?		NUjDWVNZVG:pIFfJOVA:NThwMkGgUS=>	M3n3O\|IzOzN4MkS2
ACHN	NH\tRXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXywMlAyNTFyMDFOwG0>	NV71OJlbPDhiaB?=		MVTMc4chT0l3ME2tO{46PSCP	NU\EenlkOjJ\|M{[yOFY>
St-4	NVH1TW9VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFuzTJoxNjBzLUGwNEDPxE1?	MYm0PEBp		NUPzOY5WVG:pIFfJOVA:NTdwNEegUS=>	MmruNlI{OzZ{NE[=
MKN1	NHjlZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV60dJplOC5yMT2xNFAh\|ryP	M3XtRlQ5KGh?		NFvwdndNd2diR1m1NF0uQC52MTDN	NVTE[FRqOjJ\|M{[yOFY>
MKN7	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[0b\|AvODFvMUCwJO69VQ>?	NY[xZmZ4PDhiaB?=		M2fJWGxw\yCJSUWwQU04NjZ6IF2=	MWKyNlM{PjJ2Nh?=
MKN28	M2j1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MViwMlAyNTFyMDFOwG0>	MUG0PEBp		MXPMc4chT0l3ME2tO{4xPyCP	M4fPUFIzOzN4MkS2
MKN45	NH\YSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDuXpFyOC5yMT2xNFAh\|ryP	NHKxNXE1QCCq		MWjMc4chT0l3ME2tPE4{PCCP	M2TkflIzOzN4MkS2
MKN74	NVzPVoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVKwMlAyNTFyMDFOwG0>	M4DLelQ5KGh?		NIPpNoxNd2diR1m1NF0uPy52MjDN	NYHBXJozOjJ\|M{[yOFY>
DU145	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnZZoxyOC5yMT2xNFAh\|ryP	M{npe\|Q5KGh?		NUHJeoVjVG:pIFfJOVA:NThwMU[gUS=>	NW\yUWNbOjJ\|M{[yOFY>
PC3	M4q1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PGN\|AvODFvMUCwJO69VQ>?	M{GwfFQ5KGh?		NFr6[ItNd2diR1m1NF0uQC54NjDN	NXqwNlZGOjJ\|M{[yOFY>
Trypanosoma brucei brucei	Ml;lSpVv[3Srb36gRZN{[Xl?	NHWydGgzODBibl2=	NUT5ZnFbOTJiaB?=	MlS3SG1UVw>?	NWCydJpDTGWlcnXhd4UhcW5icHjvd5Bpd3SrZInsJIlvd3OrdH;sJJBpd3OyaHH0[UBt\X[nbB?=	M1:5cVI1QDB3OUS2
Trypanosoma brucei brucei	NECxO41HfW6ldHnvckBCe3OjeR?=		NWXRfHZLOThiaB?=	M3HoRWROW09?	MUPJcohq[mm2aX;uJI9nKHKnY3XweI9zNW2nZHnheIVlKGWwZH;jfZRwe2m\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKHS{YX7z[oVzemmwIIXweIFs\Q>?	NH25U5czPDhyNUm0Oi=>
Trypanosoma brucei brucei	MkDKSpVv[3Srb36gRZN{[Xl?	NIi0NWUzODBibl2=	NV:5SGdSOTJiaB?=	MlHVSG1UVw>?	MlzkSYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>	MnruNlQ5ODV7NE[=
Trypanosoma brucei brucei	MlzlSpVv[3Srb36gRZN{[Xl?	MlG5NlAxKG6P	MnjYNVIhcA>?	NFT3PYpFVVOR	M2[5eGVn\mWldDDvckBxcG:\|cHjheIllgWylaH;sbY5mKGyndnXs	NEnPVGozPDhyNUm0Oi=>
UM-UC-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTNzNTDwUS=>	MXrTRW5ITVJ?
SBC-1	NWLx[3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTd2MjDwUS=>	NH3IPYxUSU6JRWK=
MKN1	NIL4dYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vhVmlEPTB;Mj64JI5O	MlflV2FPT0WU
NCI-H720	NUfkN\|cyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGC1TItKSzVyPUOuOVchdk1?	MVzTRW5ITVJ?
BFTC-909	M4L3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;5fpBVUUN3ME2zMlcyKG6P	M4\mVXNCVkeHUh?=
BPH-1	M4jxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGWz[HJKSzVyPUSuO\|Yhdk1?	MlvQV2FPT0WU
PC-3	Mn:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH21S4dKSzVyPUWuNFkhdk1?	MnfKV2FPT0WU
AN3-CA	M{PIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoC4TWM2OD13LkW2JI5O	NXvteoN7W0GQR1XS
HN	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTVwOU[gcm0>	MnTnV2FPT0WU
HCC2218	M2fWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XVRWlEPTB;Nj62NUBvVQ>?	NHLQNXNUSU6JRWK=
KP-4	M1q0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;NToJKSzVyPUegcm0>	NGrydppUSU6JRWK=
LU-139	NX\KTVl3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTdwN{egcm0>	NWHUbG1qW0GQR1XS
ETK-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jN[WlEPTB;Nz64PEBvVQ>?	NHnBOmpUSU6JRWK=
Ramos-2G6-4C10	NY\aPVBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DIUWlEPTB;OD60PUBvVQ>?	MWfTRW5ITVJ?
MHH-PREB-1	NUDFXHdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPT[npKSzVyPUmuNVIhdk1?	M2[4eXNCVkeHUh?=
DU-4475	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DLWGlEPTB;OT60OEBvVQ>?	Mny2V2FPT0WU
NCI-H1666	Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTlwN{Ggcm0>	M1O1U3NCVkeHUh?=
CAMA-1	MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknUTWM2OD17Lkigcm0>	MUPTRW5ITVJ?
TYK-nu	NF7QTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;STWM2OD17Lkm0JI5O	M3qyZ3NCVkeHUh?=
MFE-280	NXjiN2FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XtN2lEPTB;OT65PUBvVQ>?	MYfTRW5ITVJ?
A549	M4nPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13UVmlEPTB;MUCuNVQhdk1?	NHLHW4NUSU6JRWK=
769-P	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{GyW2lEPTB;MUCuOFQhdk1?	MXHTRW5ITVJ?
L-363	NVjYOVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvnTWM2OD1zMD62PUBvVQ>?	MorkV2FPT0WU
ES8	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLJTWM2OD1zMD65JI5O	MofoV2FPT0WU
PA-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXS[GdKSzVyPUGxMlgzKG6P	NXLOco5NW0GQR1XS
Mewo	M1:5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljmTWM2OD1zMT65PUBvVQ>?	MYXTRW5ITVJ?
HSC-3	M{CyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfvTWM2OD1zMj6yNUBvVQ>?	M3LtT3NCVkeHUh?=
H4	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HNbGlEPTB;MUKuOlchdk1?	M{Dze3NCVkeHUh?=
BB65-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\uPFFHUUN3ME2xNk44OiCwTR?=	M33nbHNCVkeHUh?=
NCI-H1793	MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPNOGRKSzVyPUGyMlgzKG6P	NFnqXFNUSU6JRWK=
KARPAS-45	NVLnNHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[wTWM2OD1zMz61NUBvVQ>?	M3vE[HNCVkeHUh?=
GCT	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTF\|Lk[4JI5O	MXrTRW5ITVJ?
EoL-1	Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHGUFNSUUN3ME2xN{46OyCwTR?=	NVW5S4Z[W0GQR1XS
LB2241-RCC	MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4P1TmlEPTB;MUSuNFEhdk1?	NV\acVhHW0GQR1XS
ES5	NVLEZ5htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTF2Lke0JI5O	M1XOWHNCVkeHUh?=
LOXIMVI	NWHwS3k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnO1TWM2OD1zND65PUBvVQ>?	M4XESXNCVkeHUh?=
COR-L105	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrJZpRKSzVyPUG1MlA1KG6P	M2e0UnNCVkeHUh?=
P12-ICHIKAWA	NFnKboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTF3LkGgcm0>	MlHkV2FPT0WU
CHL-1	NEDTV\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH70dFVKSzVyPUG1MlQ2KG6P	MUDTRW5ITVJ?
VMRC-RCZ	NYWxRZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O4SWlEPTB;MUWuOlMhdk1?	Mnv3V2FPT0WU
HH	NG\aNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{L6RmlEPTB;MUWuO{BvVQ>?	Mo\rV2FPT0WU
NUGC-3	MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjofVhjUUN3ME2xOk4{PCCwTR?=	NWryXG5vW0GQR1XS
EGI-1	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn:3TWM2OD1zNj60N{BvVQ>?	MY\TRW5ITVJ?
OS-RC-2	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF4LkS3JI5O	MYDTRW5ITVJ?
MOLT-16	MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofLTWM2OD1zNz6xOUBvVQ>?	NH3I[mNUSU6JRWK=
NCI-H209	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTF5LkK5JI5O	MknnV2FPT0WU
697	NXjoSmJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTF5LkSzJI5O	NWDyTJN1W0GQR1XS
D-56MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M333[GlEPTB;MUeuOlkhdk1?	Mo\UV2FPT0WU
VA-ES-BJ	Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTTTWM2OD1zNz64N{BvVQ>?	MULTRW5ITVJ?
EW-16	M2Cydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnqTWM2OD1zOD6wOEBvVQ>?	M2j0SHNCVkeHUh?=
HGC-27	M3rBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS4TWM2OD1zOD6wOkBvVQ>?	MnLqV2FPT0WU
ES7	M4q0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF6LkC5JI5O	MWDTRW5ITVJ?
HuH-7	M2TFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{D2WWlEPTB;MUiuOEBvVQ>?	MkXMV2FPT0WU
BCPAP	NVjweXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHJSlEyUUN3ME2xPE43PSCwTR?=	MmLlV2FPT0WU
SW1710	MlSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv0OlZKSzVyPUG4MlczKG6P	NVHxWItCW0GQR1XS
IST-MEL1	M{O2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTF6Lke3JI5O	M1rZR3NCVkeHUh?=
SF295	NUG0Rld5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy2THlKSzVyPUG4Mlk{KG6P	NGrhOWdUSU6JRWK=
RPMI-7951	Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFm3do9KSzVyPUG5MlI5KG6P	M{nyVnNCVkeHUh?=
SF126	M37XTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWWwOYFlUUN3ME2xPU41OSCwTR?=	MUTTRW5ITVJ?
GAMG	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\hbYpKSzVyPUG5MlQ5KG6P	MmTSV2FPT0WU
KNS-81-FD	NXHzfWxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3ZTWM2OD1zOT61OEBvVQ>?	NIjWS4pUSU6JRWK=
RT-112	MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTF7Lk[2JI5O	M3PSZ3NCVkeHUh?=
DEL	NIPGOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJyLkS5JI5O	NWXvfpU{W0GQR1XS
CGTH-W-1	NGTLT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoD0TWM2OD1{MD62N{BvVQ>?	NWLHS2tRW0GQR1XS
HOS	M4TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rMdmlEPTB;MkGuNFYhdk1?	NWO1PVE4W0GQR1XS
ES4	M1W5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHxTWM2OD1{MT6wPEBvVQ>?	MUfTRW5ITVJ?
RXF393	M3nVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnn0TWM2OD1{MT60OUBvVQ>?	NEX5XHJUSU6JRWK=
NCI-H2030	NEGy[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIS0SoxKSzVyPUKxMlUzKG6P	MVXTRW5ITVJ?
YH-13	NWi3ZWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn63TWM2OD1{MT64PEBvVQ>?	M365RXNCVkeHUh?=
HT-1080	M3rIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17hbGlEPTB;MkGuPVMhdk1?	NGTNZ\|JUSU6JRWK=
NCI-SNU-1	NVTreHdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHFTWM2OD1{MT65OUBvVQ>?	NFi0b4RUSU6JRWK=
G-402	NWnQ[phqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTJ{LkG2JI5O	MoixV2FPT0WU
786-0	M{fJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fM[mlEPTB;MkKuNlkhdk1?	NFLFUItUSU6JRWK=
ME-180	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVm5SYZMUUN3ME2yNk41OyCwTR?=	NHvlS4JUSU6JRWK=
NB69	NX:4PZMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTPTWM2OD1{Mj61N{BvVQ>?	MlfqV2FPT0WU
J-RT3-T3-5	Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTRbIlKSzVyPUKyMlk3KG6P	M2jjfXNCVkeHUh?=
TGBC1TKB	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrTWG5TUUN3ME2yN{4xPSCwTR?=	NGmyNFNUSU6JRWK=
SW780	NUjicIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\VVlFKSzVyPUKzMlE{KG6P	NUfPXFBiW0GQR1XS
MG-63	NUOxPGxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDzTWM2OD1{Mz60OUBvVQ>?	M{\EN3NCVkeHUh?=
BV-173	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIG4fmlKSzVyPUKzMlg4KG6P	NWHhVllzW0GQR1XS
CAL-51	M4n0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rscWlEPTB;MkOuPFkhdk1?	MnHRV2FPT0WU
A375	NIDSS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV61R25{UUN3ME2yN{46OyCwTR?=	NVrNRmlzW0GQR1XS
MEL-HO	NIPqeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrtbplvUUN3ME2yOE4xPCCwTR?=	MljvV2FPT0WU
EFO-27	M1f3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ficGlEPTB;MkSuN\|Mhdk1?	NVeyVHdWW0GQR1XS
Hs-578-T	NGLoTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJ2LkW4JI5O	M3v6bXNCVkeHUh?=
NBsusSR	NYLYfWJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zQb2lEPTB;MkSuOkBvVQ>?	NFr2TW9USU6JRWK=
CTB-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTJ2Lk[3JI5O	MV;TRW5ITVJ?
FTC-133	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4K3VWlEPTB;MkWuNUBvVQ>?	NFr3XYFUSU6JRWK=
MOLT-4	NGrPT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHrTWM2OD1{NT6xNkBvVQ>?	MljzV2FPT0WU
HO-1-N-1	M{D2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWr4PIl5UUN3ME2yOU4yPSCwTR?=	Mn;oV2FPT0WU
ES3	NUK1ZlR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{j3VGlEPTB;MkWuNlIhdk1?	M{HPXXNCVkeHUh?=
TI-73	NIP5T4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33ZTmlEPTB;MkWuNlghdk1?	NU\oeGYzW0GQR1XS
MPP-89	NHeweYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIX0VItKSzVyPUK1MlMzKG6P	MkPqV2FPT0WU
KYSE-150	M3zJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3WTWM2OD1{NT64PUBvVQ>?	M1PIW3NCVkeHUh?=
LXF-289	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DSSGlEPTB;Mk[uNFQhdk1?	M2X3SnNCVkeHUh?=
SK-LU-1	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTWV5NSUUN3ME2yOk4yPyCwTR?=	NED6PHRUSU6JRWK=
HOP-92	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;OVnF4UUN3ME2yOk41QCCwTR?=	NYH6Nm5wW0GQR1XS
HuO9	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLlfWtuUUN3ME2yOk44PiCwTR?=	NV7JUY8yW0GQR1XS
SW962	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJ4Lke2JI5O	MVrTRW5ITVJ?
RS4-11	MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJ4LkmxJI5O	NGnXdIJUSU6JRWK=
NCI-H292	NF;YdVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJ5IH7N	MlLkV2FPT0WU
DB	NH3VeWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS0TWM2OD1{Nz6zOkBvVQ>?	MWXTRW5ITVJ?
SW1088	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXXcnJKSzVyPUK4MlI6KG6P	NEnqNHdUSU6JRWK=
A204	NIDEbJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJ6LkS3JI5O	M4\JWnNCVkeHUh?=
A3-KAW	NWXzfWN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\ObWlEPTB;MkiuOlQhdk1?	NUPSUmduW0GQR1XS
MV-4-11	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWjGPW16UUN3ME2yPE44KG6P	MWjTRW5ITVJ?
ES1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXXUmp2UUN3ME2yPE45PCCwTR?=	NXLD[phmW0GQR1XS
ONS-76	NFG1N5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUW2VoVHUUN3ME2yPU4xPSCwTR?=	MoSwV2FPT0WU
D-263MG	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;leWV2UUN3ME2yPU4{PSCwTR?=	NXvhflNwW0GQR1XS
U-2-OS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX71R4s{UUN3ME2yPU42KG6P	NFTubmhUSU6JRWK=
T98G	NFj5[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[y[JpKSzVyPUK5Mlg5KG6P	NEnWTVZUSU6JRWK=
GI-ME-N	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHi4b2VKSzVyPUK5MlkyKG6P	NWrkZYJGW0GQR1XS
BHT-101	MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjPV5ZKSzVyPUOwMlA2KG6P	NELTdI9USU6JRWK=
NOS-1	M2[xdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzycZhKSzVyPUOwMlEzKG6P	NGS5[FhUSU6JRWK=
AsPC-1	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\wWVFKSzVyPUOwMlIhdk1?	MVfTRW5ITVJ?
QIMR-WIL	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4ixZ2lEPTB;M{CuOkBvVQ>?	NXXV[WNxW0GQR1XS
JVM-3	NYSwb4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzN[I1KSzVyPUOwMlg{KG6P	MnzEV2FPT0WU
KU-19-19	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLacYtZUUN3ME2zNU4yOyCwTR?=	NI\rcZJUSU6JRWK=
OVCAR-8	M{PTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTNzLkK2JI5O	NVi2UGVqW0GQR1XS
BEN	NUfOSY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHpTWM2OD1\|MT62N{BvVQ>?	NYfBfYhkW0GQR1XS
BE-13	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jwTmlEPTB;M{GuPFIhdk1?	NEfzZ5JUSU6JRWK=
EW-18	M4XCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTKW45KSzVyPUOxMlg3KG6P	MlTSV2FPT0WU
ECC10	M1O2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\EdmlEPTB;M{GuPVUhdk1?	NWPyN2dnW0GQR1XS
CTV-1	M3frcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3lTWM2OD1\|Mj64NkBvVQ>?	NGf1cHlUSU6JRWK=
COLO-800	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLLTppKSzVyPUOyMlkzKG6P	NXzBR\|QyW0GQR1XS
A2058	NWfjR5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTN\|LkK1JI5O	M2XiN3NCVkeHUh?=
VM-CUB-1	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPmTWM2OD1\|Mz60N{BvVQ>?	M{X4d3NCVkeHUh?=
Ca9-22	M1vCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjQcIZZUUN3ME2zN{42PSCwTR?=	NI\GcldUSU6JRWK=
COLO-684	NHm3PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLKVJlKSzVyPUOzMlU5KG6P	MX;TRW5ITVJ?
RPMI-8226	NX;qcXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTN\|LkiyJI5O	NFjCd5hUSU6JRWK=
SK-NEP-1	MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4X2VWlEPTB;M{SuNVUhdk1?	NGLZTVRUSU6JRWK=
Becker	M2LocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTN2LkKxJI5O	MlnWV2FPT0WU
NCI-H28	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHRWpZ{UUN3ME2zOE41PCCwTR?=	MlHBV2FPT0WU
CAL-120	NF;WPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2n4ZmlEPTB;M{SuO\|Ihdk1?	MW\TRW5ITVJ?
MDA-MB-157	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3OTWM2OD1\|NT60NUBvVQ>?	MVfTRW5ITVJ?
OVCAR-5	NWHwdoRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTN3LkS3JI5O	M3jUcnNCVkeHUh?=
LAMA-84	M{LBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\KS2lEPTB;M{WuPFchdk1?	M3;HVXNCVkeHUh?=
CAKI-1	M{nySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml62TWM2OD1\|Nj60N{BvVQ>?	M2H2N3NCVkeHUh?=
Daoy	MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\UTWM2OD1\|Nj63JI5O	NGTTfoNUSU6JRWK=
CAL-62	NXP6WolGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXGUZA1UUN3ME2zOk45PiCwTR?=	MVPTRW5ITVJ?
8-MG-BA	M1nsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTN5LkK1JI5O	MXnTRW5ITVJ?
8505C	NHOyNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LTTmlEPTB;M{euOVEhdk1?	NWC4do05W0GQR1XS
LNCaP-Clone-FGC	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;DV\|hKSzVyPUO3MlU6KG6P	NVPUT5pPW0GQR1XS
CAL-39	NVK3R4tLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTN5Lkmgcm0>	M2CyenNCVkeHUh?=
MN-60	NF7nfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTN5Lkm2JI5O	MULTRW5ITVJ?
RKO	NGDPTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTN6LkOzJI5O	MYnTRW5ITVJ?
U251	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7SZWtKSzVyPUO4MlQ{KG6P	M4DNWHNCVkeHUh?=
SJSA-1	M2K2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4m4eWlEPTB;M{iuOVQhdk1?	NG\rSXhUSU6JRWK=
CAL-12T	M2H2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTSUXlKSzVyPUO4MlYhdk1?	MX\TRW5ITVJ?
HCC1419	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmC0TWM2OD1\|OD63NUBvVQ>?	MmLtV2FPT0WU
CO-314	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTN6Lke0JI5O	NXfCdlNrW0GQR1XS
LB1047-RCC	M3u2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\SWWlEPTB;M{iuPFEhdk1?	MnHQV2FPT0WU
A101D	NWDJPY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HuVWlEPTB;M{iuPVchdk1?	MoHGV2FPT0WU
MDA-MB-175-VII	NWi3NZhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3TTWM2OD1\|OT61NUBvVQ>?	Mnr2V2FPT0WU
MZ2-MEL	NVjHPHo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYC1cFlqUUN3ME2zPU43PiCwTR?=	MVXTRW5ITVJ?
NB5	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\B[GlEPTB;NECuOlQhdk1?	MorwV2FPT0WU
G-401	M3jOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTRyLkiyJI5O	M4LqWHNCVkeHUh?=
HT	NV\RNnZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\BXo1CUUN3ME20NU4xOiCwTR?=	MUnTRW5ITVJ?
8305C	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTRzLki3JI5O	NVvMT\|BOW0GQR1XS
BHY	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3wXGhrUUN3ME20Nk44OiCwTR?=	MVjTRW5ITVJ?
NTERA-S-cl-D1	M4X6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn6NJh3UUN3ME20N{BvVQ>?	MUHTRW5ITVJ?
T-24	M1LU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTR\|LkizJI5O	M3HWdXNCVkeHUh?=
EPLC-272H	NFjXdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fiVmlEPTB;NESuN\|khdk1?	Mmn4V2FPT0WU
PSN1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTR2LkSgcm0>	NHPaU2JUSU6JRWK=
NCI-H2452	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHqTWM2OD12ND61PEBvVQ>?	NX2xc4E4W0GQR1XS
KS-1	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfpUJBKSzVyPUS0MlY3KG6P	MmTIV2FPT0WU
HD-MY-Z	NH63TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvZTWM2OD12ND65NkBvVQ>?	M1\FcnNCVkeHUh?=
KNS-62	M2nRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XUV2lEPTB;NEWuN\|ghdk1?	MoTMV2FPT0WU
NOMO-1	M1HNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jyZmlEPTB;NEWuPFchdk1?	MmjwV2FPT0WU
SK-HEP-1	M36zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\pOWlEPTB;NE[uNFQhdk1?	NGjSdYxUSU6JRWK=
IGR-1	M1rSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDMTWM2OD12Nj6xN{BvVQ>?	MU\TRW5ITVJ?
KYSE-180	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTR4LkG3JI5O	MWnTRW5ITVJ?
EW-22	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXoTYZKSzVyPUS2MlIhdk1?	MVXTRW5ITVJ?
NCI-H1355	M1e0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\5TVdKSzVyPUS2MlM1KG6P	Mny0V2FPT0WU
DOHH-2	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X5OWlEPTB;NE[uN\|chdk1?	NV64R3hUW0GQR1XS
A4-Fuk	M1XySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rEeWlEPTB;NE[uOVIhdk1?	MlT3V2FPT0WU
PC-14	NXW3e\|FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjpTYFFUUN3ME20Ok42PyCwTR?=	MmLxV2FPT0WU
TE-5	NFnr[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDETWM2OD12Nj64OEBvVQ>?	NWPqT5hWW0GQR1XS
LB996-RCC	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTR5LkG5JI5O	MYXTRW5ITVJ?
NCI-H1623	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTR5Lke2JI5O	Mn\3V2FPT0WU
NCI-H1155	NFPheG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLpTWM2OD12OD6zNkBvVQ>?	NXTacFlZW0GQR1XS
LoVo	M{flZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrhbFBKSzVyPUS4MlQhdk1?	M{\oUXNCVkeHUh?=
MCF7	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTR6LkW4JI5O	NULUSm4zW0GQR1XS
AGS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT3TWM2OD12OD63O{BvVQ>?	NHvxUpBUSU6JRWK=
PFSK-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDJVW1mUUN3ME20PU4xPiCwTR?=	M3;OWHNCVkeHUh?=
22RV1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTjTWM2OD12OT6wPUBvVQ>?	NEjEeGhUSU6JRWK=
COR-L23	NGTtOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrTXGs4UUN3ME20PU4yPiCwTR?=	NWKwcWJqW0GQR1XS
D-283MED	NVL5coF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fCb2lEPTB;NEmuOlEhdk1?	MmDKV2FPT0WU
SW982	M13lTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HnOmlEPTB;NEmuPVEhdk1?	NYP0RmltW0GQR1XS
SW620	M4riU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDaWJkzUUN3ME21NE4{PiCwTR?=	Mn:4V2FPT0WU
KYSE-140	NW\DPWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLHOXlbUUN3ME21NE42PSCwTR?=	MXXTRW5ITVJ?
GCIY	NFvNOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\lTWM2OD13MD62O{BvVQ>?	MlTjV2FPT0WU
MHH-ESS-1	NVj1bmpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrGeGlYUUN3ME21NU46PSCwTR?=	M{HRS3NCVkeHUh?=
D-423MG	M3L0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXBTWM2OD13Mj6wPEBvVQ>?	MUXTRW5ITVJ?
SF539	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLhTWM2OD13Mj6zOUBvVQ>?	Mki3V2FPT0WU
RPMI-2650	NX7vPYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfaTpNkUUN3ME21Nk43QSCwTR?=	Mme5V2FPT0WU
GR-ST	NVXye3JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjPPVNpUUN3ME21Nk45PyCwTR?=	MXnTRW5ITVJ?
YKG-1	NXjOd\|I4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfINlU{UUN3ME21N{BvVQ>?	NVjRS3V4W0GQR1XS
SK-MES-1	M{GxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonHTWM2OD13Mz6yOkBvVQ>?	MnvlV2FPT0WU
HLE	NGLHTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTV\|LkS3JI5O	MlLDV2FPT0WU
RVH-421	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL5dlA{UUN3ME21N{43PyCwTR?=	MnP3V2FPT0WU
C32	NHTEUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvKNIRyUUN3ME21N{45OyCwTR?=	MUfTRW5ITVJ?
GB-1	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfRdXY{UUN3ME21OE4zKG6P	NFHqcZpUSU6JRWK=
SNB75	NEnIPYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrKPIR1UUN3ME21OE4zPiCwTR?=	MnrsV2FPT0WU
EM-2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoC1TWM2OD13ND60JI5O	MX\TRW5ITVJ?
RH-1	NFz1em1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTV2Lkegcm0>	NFvPXo5USU6JRWK=
NKM-1	M3rvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnuc4ZKSzVyPUW0MlgyKG6P	NXyyWWQ{W0GQR1XS
NCI-H2405	NHS0bWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj5XppHUUN3ME21OE45QCCwTR?=	MUfTRW5ITVJ?
KYSE-450	NWDDSFZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfMNXBMUUN3ME21OU4yPiCwTR?=	NWf6ZVE6W0GQR1XS
A704	NFnDfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLvTWM2OD13NT61PUBvVQ>?	M17ieXNCVkeHUh?=
HAL-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlq1TWM2OD13NT64N{BvVQ>?	NXm3UVJFW0GQR1XS
TE-11	MlvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojzTWM2OD13NT65PUBvVQ>?	MUfTRW5ITVJ?
DOK	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLOdnBCUUN3ME21Ok4xOiCwTR?=	MVfTRW5ITVJ?
KY821	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnNcW13UUN3ME21Ok4zKG6P	MUfTRW5ITVJ?
KGN	NGXMT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvQTndKSzVyPUW2MlMzKG6P	M3O4[HNCVkeHUh?=
MC116	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofOTWM2OD13Nz64JI5O	MU\TRW5ITVJ?
PANC-08-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jZSGlEPTB;NUiuNFEhdk1?	MWrTRW5ITVJ?
KE-37	M1e1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTV6Lke3JI5O	NFHSOm9USU6JRWK=
KYSE-410	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn2xTWM2OD13OT60O{BvVQ>?	Ml\2V2FPT0WU
RO82-W-1	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn[2TWM2OD13OT65JI5O	NXjKcnBRW0GQR1XS
M14	NFPDZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTZyLkC0JI5O	MlSzV2FPT0WU
GI-1	M3;Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTZyLkOgcm0>	Mn\DV2FPT0WU
ML-2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXKwOFY3UUN3ME22NE43OiCwTR?=	NIfpVnVUSU6JRWK=
BFTC-905	M4XLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXINmo6UUN3ME22NE43PSCwTR?=	Ml7JV2FPT0WU
DMS-273	NX\4eHNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3sTWM2OD14MD64O{BvVQ>?	M3foUXNCVkeHUh?=
MDA-MB-361	NX71VZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37aW2lEPTB;NkGgcm0>	Ml35V2FPT0WU
MSTO-211H	NEPPWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTZ\|LkWxJI5O	NEjZeWxUSU6JRWK=
MEG-01	M1j0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3G3fWlEPTB;NkOuOVIhdk1?	M1L5RXNCVkeHUh?=
M059J	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTFTWM2OD14Mz61PEBvVQ>?	MWnTRW5ITVJ?
LN-405	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf2TWM2OD14Mz64OUBvVQ>?	NVH0eIU5W0GQR1XS
NCI-H1581	NHHZXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTPTWM2OD14ND6wN{BvVQ>?	MWTTRW5ITVJ?
TCCSUP	NIHUXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlr1TWM2OD14ND61N{BvVQ>?	MnLFV2FPT0WU
SW872	MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPPTWM2OD14ND61O{BvVQ>?	MWrTRW5ITVJ?
KYSE-510	NUDYVIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLjTWM2OD14NT63OUBvVQ>?	M3K1[nNCVkeHUh?=
NCI-H1792	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXVTWM2OD14Nj6xOUBvVQ>?	MlfsV2FPT0WU
SW13	MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIOx[ZBKSzVyPU[2MlUhdk1?	NITNOItUSU6JRWK=
TE-8	M{PpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLnTWM2OD14Nj61NkBvVQ>?	NFPpVoxUSU6JRWK=
SCH	NEDTZ\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zyRWlEPTB;NkeuNUBvVQ>?	MmWxV2FPT0WU
NEC8	M1LCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTZ5LkK0JI5O	NWfobXlYW0GQR1XS
HuO-3N1	NYm3XFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\VUGlEPTB;NkeuN\|Ehdk1?	NI[xUYZUSU6JRWK=
EFM-19	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjGVVBKSzVyPU[3MlUhdk1?	MVPTRW5ITVJ?
HEC-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTZ5LkWyJI5O	MUXTRW5ITVJ?
T47D	NYPLUIE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;ORoJKSzVyPU[3Mlg4KG6P	NGj4b29USU6JRWK=
SNU-423	M1K0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTZ5Lkm4JI5O	NGjGWZRUSU6JRWK=
WM-115	MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUSw[phtUUN3ME22PE4yPCCwTR?=	NFPycodUSU6JRWK=
CaR-1	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PQV2lEPTB;NkiuNlUhdk1?	MWrTRW5ITVJ?
KU812	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXYfoFxUUN3ME22PE43QSCwTR?=	MmnrV2FPT0WU
AM-38	NUKyfZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHib3BkUUN3ME22PU4{OSCwTR?=	M1XNZnNCVkeHUh?=
KOSC-2	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXWVWRiUUN3ME22PU46PyCwTR?=	MmTNV2FPT0WU
MC-IXC	M{DSUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn62TWM2OD15MD6wPEBvVQ>?	NX7pc\|JpW0GQR1XS
SCC-4	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXpTWM2OD15MT6zPEBvVQ>?	M3LHVnNCVkeHUh?=
Calu-3	NHKzR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33VW2lEPTB;N{GuPVghdk1?	MXvTRW5ITVJ?
RPMI-8866	NHLmOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzwTWM2OD15Mj64NkBvVQ>?	NXztV2xTW0GQR1XS
OVCAR-4	NXvHT21yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfRSmJKSzVyPUezMlM3KG6P	M2nKbXNCVkeHUh?=
OAW-42	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;tUGlEPTB;N{OuN\|khdk1?	NH\wTnlUSU6JRWK=
ATN-1	NFHabmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrUN2tKSzVyPUezMlg4KG6P	M1;lbHNCVkeHUh?=
CHP-212	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHlTWM2OD15ND65OUBvVQ>?	M{jFXXNCVkeHUh?=
C2BBe1	M3z5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jFWGlEPTB;N{WuNFMhdk1?	NW\WWWFSW0GQR1XS
A498	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTd3LkG1JI5O	NVroNHBRW0GQR1XS
SH-4	NWK4XmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfxZ5lbUUN3ME23OU4zOSCwTR?=	MVfTRW5ITVJ?
SNU-449	Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoK2TWM2OD15NT63PUBvVQ>?	MWLTRW5ITVJ?
RD	NV70ZW1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDr[FRKSzVyPUe1Mlg3KG6P	MWnTRW5ITVJ?
PANC-03-27	M4LCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTd4LkK1JI5O	NVjkZVYxW0GQR1XS
S-117	M1XUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjlZ5hKSzVyPUe2MlI4KG6P	MVrTRW5ITVJ?
SK-MEL-2	M{HrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILF[HdKSzVyPUe2Mlc2KG6P	MX\TRW5ITVJ?
LK-2	NFnSNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWq5b4NZUUN3ME23O{4xPSCwTR?=	MVzTRW5ITVJ?
CP50-MEL-B	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnXW5VKSzVyPUe3MlQhdk1?	Mnz0V2FPT0WU
647-V	NELldIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfzTWM2OD15OD6wO{BvVQ>?	MVnTRW5ITVJ?
LU-134-A	M33LdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2LwZWlEPTB;N{muNFMhdk1?	NYLUNI41W0GQR1XS
5637	M4PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkH2TWM2OD15OT6yN{BvVQ>?	MmPVV2FPT0WU
NCI-H1437	NE\YcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TRN2lEPTB;OECuOUBvVQ>?	M{jSV3NCVkeHUh?=
NCI-H460	M17tWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\FdlhKSzVyPUixMlI{KG6P	NUmwU2Y2W0GQR1XS
BxPC-3	NWHxVW9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{T5fmlEPTB;OEGuOFYhdk1?	MW\TRW5ITVJ?
CAN	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRThzLki0JI5O	MmT6V2FPT0WU
KINGS-1	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vCRmlEPTB;OEKuN\|Ihdk1?	NIX6Z29USU6JRWK=
OCUB-M	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmL1TWM2OD16Mj60NUBvVQ>?	NIPZUWVUSU6JRWK=
KALS-1	NV;Jc5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTXcWZKSzVyPUiyMlU1KG6P	M1rGXXNCVkeHUh?=
OCI-AML2	M{npRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnUfGVKSzVyPUiyMlYyKG6P	M4W4ZnNCVkeHUh?=
A253	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;DTWM2OD16Mj62OUBvVQ>?	MWHTRW5ITVJ?
LCLC-97TM1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nQW2lEPTB;OEKuPFYhdk1?	NVf5enl{W0GQR1XS
NCI-H520	Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTh\|LkC2JI5O	NXy1UolWW0GQR1XS
P30-OHK	NVP1PIN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\1bYNxUUN3ME24N{42KG6P	NVTOU45MW0GQR1XS
SBC-5	M4PTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\mZm9KSzVyPUizMlUzKG6P	M3n0N3NCVkeHUh?=
HCE-T	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTh\|Lke0JI5O	MknIV2FPT0WU
JEG-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;4TWM2OD16ND6xJI5O	MXzTRW5ITVJ?
KG-1	M{XRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTh2LkK0JI5O	NH;WSFJUSU6JRWK=
MIA-PaCa-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTh2LkW0JI5O	NIDWSG5USU6JRWK=
CAL-33	NGXoN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDtblFkUUN3ME24OU4xQCCwTR?=	NH7pWolUSU6JRWK=
639-V	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;qZVJ{UUN3ME24OU41OiCwTR?=	M1q1WXNCVkeHUh?=
NCI-H1048	M3;rSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTh4LkOxJI5O	MUTTRW5ITVJ?
NCI-H1573	NEW3T2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3M[4NKSzVyPUi3MlQ5KG6P	MXzTRW5ITVJ?
NCI-H2228	MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTwRllCUUN3ME24PE4zPiCwTR?=	M2DoXnNCVkeHUh?=
NB14	NEfPbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf5[IFkUUN3ME24PE4{KG6P	NVLxWIdmW0GQR1XS
SCC-25	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTh7LkiyJI5O	MnzBV2FPT0WU
A431	NWrMXlZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PBVGlEPTB;OEmuPVchdk1?	NEKybmNUSU6JRWK=
SN12C	NILXd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;6TWM2OD17MD62NkBvVQ>?	MonwV2FPT0WU
HuCCT1	NIr6U\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPCVVkyUUN3ME25NE44PiCwTR?=	MUfTRW5ITVJ?
LS-123	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTl{LkG4JI5O	NULVTVVPW0GQR1XS
CAL-85-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XiO2lEPTB;OUKuOFghdk1?	NF;iSGFUSU6JRWK=
ES6	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;2TWM2OD17Mj64N{BvVQ>?	MYTTRW5ITVJ?
NCI-H650	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTl2LkC5JI5O	MVnTRW5ITVJ?
NCI-H446	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3exRWlEPTB;OUWuNVIhdk1?	NEn1eoRUSU6JRWK=
EW-13	NFPQXZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLqTWM2OD17NT63OUBvVQ>?	MX\TRW5ITVJ?
HSC-2	M1THOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfkTWM2OD17NT64PUBvVQ>?	NGLjemlUSU6JRWK=
U031	NIKzR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTl4LkezJI5O	NGmyOZFUSU6JRWK=
EW-11	NWrVSmlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTl4Lki4JI5O	NYDZUYFzW0GQR1XS
GAK	NFKzbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LOfmlEPTB;OUiuPVMhdk1?	MoDUV2FPT0WU
SK-OV-3	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[5UGlEPTB;MUCwMlA4KG6P	NEXUPIZUSU6JRWK=
OMC-1	NYriW5hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIryd\|dKSzVyPUGwNE4yQCCwTR?=	Mk\FV2FPT0WU
TK10	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTFyMD6yNUBvVQ>?	M2LzT3NCVkeHUh?=
EKVX	M2fJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j5cWlEPTB;MUCwMlYhdk1?	M2XmfXNCVkeHUh?=
Detroit562	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3RcmZKSzVyPUGwNk4yPyCwTR?=	Ml\WV2FPT0WU
SF268	M4rScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHkTWM2OD1zMEKuN\|Qhdk1?	MX7TRW5ITVJ?
SNU-387	NYn1[phET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DEU2lEPTB;MUC0MlE4KG6P	NVnSXYhpW0GQR1XS
MDA-MB-231	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;EZnA3UUN3ME2xNFUvODZibl2=	M{OxVHNCVkeHUh?=
NCI-H1563	Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTFyNT6xPEBvVQ>?	NEXQPVVUSU6JRWK=
D-502MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoexTWM2OD1zMEWuO{BvVQ>?	NIH0WVZUSU6JRWK=
A2780	M3XyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmr4TWM2OD1zME[uOFchdk1?	MWPTRW5ITVJ?
IA-LM	NY\MdGxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2SzUGlEPTB;MUC3MlUyKG6P	M3v1RnNCVkeHUh?=
D-392MG	NIrEVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFyNz61OEBvVQ>?	MVjTRW5ITVJ?
MS-1	NES0[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\0OWlEPTB;MUC3MlcyKG6P	NX31W4NEW0GQR1XS
SW1990	NH;iZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETwSmFKSzVyPUGwPE42PCCwTR?=	MmLtV2FPT0WU
HEL	NYjYPHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnBboN3UUN3ME2xNFkvOjlibl2=	MlvRV2FPT0WU
SW1573	NGPoPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTFyOT6zNUBvVQ>?	NHiz[HlUSU6JRWK=
SW1783	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFzMD6yNkBvVQ>?	MlfQV2FPT0WU
COLO-680N	NYfQPW1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1Tle2lEPTB;MUGwMlc3KG6P	NIfuOo5USU6JRWK=
NCI-N87	NWmxU3FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3neHpKSzVyPUGxNU4xPCCwTR?=	MUnTRW5ITVJ?
SK-MEL-28	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlKwTWM2OD1zMUGuOVUhdk1?	MWDTRW5ITVJ?
BT-20	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2H1[WlEPTB;MUGyMlAyKG6P	Mm[2V2FPT0WU
NCI-H1648	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTQVFVKSzVyPUGxN{BvVQ>?	NHrRcYJUSU6JRWK=
no-11	M3vpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTFzMz6yPEBvVQ>?	MW\TRW5ITVJ?
MOLT-13	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TWc2lEPTB;MUGzMlQ1KG6P	MnXiV2FPT0WU
NCI-H2170	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDvO282UUN3ME2xNVQvPTFibl2=	NVTiWpZFW0GQR1XS
HTC-C3	NIrnSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFX6SYNKSzVyPUGxOk45PSCwTR?=	MkP3V2FPT0WU
LU-99A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nIbmlEPTB;MUG3MlIyKG6P	M4qzRXNCVkeHUh?=
HCC2998	M2qzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlGzTWM2OD1zMUeuPVIhdk1?	NUG3cGx4W0GQR1XS
NB13	NGX1S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPLTWM2OD1zMUeuPVkhdk1?	MUPTRW5ITVJ?
GT3TKB	NGHuZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLEe2JKSzVyPUGxPE4xQCCwTR?=	MVrTRW5ITVJ?
BT-549	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTFzOD65OUBvVQ>?	M2n1d3NCVkeHUh?=
NCI-H747	NU\TWIo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{S2UmlEPTB;MUG5MlM1KG6P	NXvrN5g1W0GQR1XS
EW-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrHXI1KSzVyPUGyNE4zKG6P	MmHEV2FPT0WU
LB831-BLC	NY\zNpdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\YTWM2OD1zMkCuOlMhdk1?	MmHmV2FPT0WU
NMC-G1	M2jwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XZS2lEPTB;MUKxMlEyKG6P	MVHTRW5ITVJ?
COLO-679	M3nkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fhc2lEPTB;MUKyMlE2KG6P	MYPTRW5ITVJ?
HL-60	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTF{Mz6xJI5O	NXrqbY1HW0GQR1XS
MKN7	M4OyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3EcYxEUUN3ME2xNlMvQDNibl2=	M1r5fnNCVkeHUh?=
RERF-LC-MS	NGi1V3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHBc\|ZKSzVyPUGyOE4{OSCwTR?=	M{izR3NCVkeHUh?=
DMS-114	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvONmdGUUN3ME2xNlUvODlibl2=	MX3TRW5ITVJ?
HuP-T4	NGD0NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF{Nj65O{BvVQ>?	MlPxV2FPT0WU
HCC2157	NY\EVpMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XsWmlEPTB;MUK3MlUhdk1?	NYn4TJZNW0GQR1XS
SKG-IIIa	M4fLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF{OD64JI5O	NG\McXBUSU6JRWK=
HCT-116	NILMe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDSe5dNUUN3ME2xN\|AvPjRibl2=	Mnf4V2FPT0WU
BB30-HNC	NFvWfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTF\|MD63PEBvVQ>?	MlTjV2FPT0WU
KYSE-270	NIPrNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFy0eIVKSzVyPUGzNE45QCCwTR?=	MnG3V2FPT0WU
MFM-223	NYTDVmt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF\|MT61NUBvVQ>?	M{nVXXNCVkeHUh?=
NH-12	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTF\|Mj65PUBvVQ>?	MV7TRW5ITVJ?
U-118-MG	M1fxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTF\|Mz62NkBvVQ>?	NYLXNHNpW0GQR1XS
ESS-1	M4LPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\0eYpKSzVyPUGzOU4yQCCwTR?=	NFHlNmxUSU6JRWK=
D-247MG	NHviPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfJTWM2OD1zM{WuNlEhdk1?	NH:zPFNUSU6JRWK=
IGROV-1	M323Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTF\|NT63OkBvVQ>?	MkP2V2FPT0WU
C-33-A	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3OTWM2OD1zM{WuPVchdk1?	M1L4TnNCVkeHUh?=
NCI-H1693	MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTF\|Nj6xNkBvVQ>?	NY\1R\|NIW0GQR1XS
MLMA	NUTnfHFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPCTWM2OD1zM{[uOVghdk1?	Mo\5V2FPT0WU
SK-N-AS	M{XaRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXVTWM2OD1zM{euNVchdk1?	MoXUV2FPT0WU
NCI-H1755	M3HQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF\|OD64OUBvVQ>?	M4\QSnNCVkeHUh?=
CHP-134	NELiNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTF\|OT61OUBvVQ>?	NGGwdXNUSU6JRWK=
LS-513	M1;mZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MniwTWM2OD1zNECuPVEheE1?	NYr5e5l3W0GQR1XS
TE-12	NWX2foRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XzXWlEPTB;MUSwMlk{KG6P	NV3ue2tZW0GQR1XS
KNS-42	M4fhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXyxPVlkUUN3ME2xOFQvOyCwTR?=	NWDoSFBwW0GQR1XS
SJRH30	Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvESGJVUUN3ME2xOFQvPDRibl2=	MV;TRW5ITVJ?
NCI-H1092	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTF2ND61NkBvVQ>?	MXzTRW5ITVJ?
H-EMC-SS	NGrwWlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULUbXMzUUN3ME2xOFYvQDFibl2=	MmHPV2FPT0WU
SK-MEL-3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnuToNZUUN3ME2xOFcvPTVibl2=	MULTRW5ITVJ?
SK-N-FI	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPoeJdKSzVyPUG0O{42QSCwTR?=	NXvtUXh7W0GQR1XS
NCI-H2126	MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[3WVZKSzVyPUG0PE4yPSCwTR?=	MXrTRW5ITVJ?
NCI-H1299	NX7rd41CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DFbWlEPTB;MUWwMlIzKG6P	NW\2[od{W0GQR1XS
CFPAC-1	NVnaWIxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTiTWM2OD1zNUCuOlYhdk1?	M2nrdHNCVkeHUh?=
NCI-H661	NG\5OWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LpSmlEPTB;MUWxMlI3KG6P	M{DifHNCVkeHUh?=
KYSE-70	NFe4WVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HQSWlEPTB;MUWxMlc6KG6P	MYTTRW5ITVJ?
SW900	M1r0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;oSFZKSzVyPUG1OE43PSCwTR?=	M121[HNCVkeHUh?=
Ca-Ski	NV76SIJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPQTWM2OD1zNU[uN\|khdk1?	MY\TRW5ITVJ?
HPAF-II	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVf3OoFoUUN3ME2xOVYvPDdibl2=	NFnIRpFUSU6JRWK=
LB2518-MEL	NVmwNnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LWdWlEPTB;MUW3MlEhdk1?	Ml\WV2FPT0WU
LC-2-ad	MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTF3OD62NkBvVQ>?	M{jC[3NCVkeHUh?=
HCC1806	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LTTWlEPTB;MU[3Mlg5KG6P	MnzYV2FPT0WU
UACC-62	M2nWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTF4OD6wPUBvVQ>?	NI[2dpZUSU6JRWK=
KM-H2	NYn5UHlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPOTWM2OD1zN{CuOVghdk1?	MkL3V2FPT0WU
NCI-H2347	NFjxZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTm[mx1UUN3ME2xO\|IvPzJibl2=	NWXweVhJW0GQR1XS
SCC-15	NVu4VHJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTF5Mz62OkBvVQ>?	NFPPO2tUSU6JRWK=
BB49-HNC	NH7MUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTF5Mz64NUBvVQ>?	MXrTRW5ITVJ?
GMS-10	NILofItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHO3VFlKSzVyPUG3N{46PCCwTR?=	NX\NbFdlW0GQR1XS
NCI-H2052	M33SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PoOmlEPTB;MUe0Mlkhdk1?	M37tcHNCVkeHUh?=
SW626	M4PGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7aTWM2OD1zN{[uNFYhdk1?	MlG2V2FPT0WU
MDA-MB-415	M3Xp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETHbY9KSzVyPUG3Ok43OSCwTR?=	M2LRcHNCVkeHUh?=
Saos-2	NX[4R2xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnSRW9KSzVyPUG3PU4{PSCwTR?=	NGLEbFhUSU6JRWK=
DK-MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoS0TWM2OD1zOECuN{BvVQ>?	NXPFW5pkW0GQR1XS
SNU-C2B	M13F[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LjdWlEPTB;MUiwMlc{KG6P	MlT2V2FPT0WU
A427	M33wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PG[WlEPTB;MUiyMlU4KG6P	MkTLV2FPT0WU
KP-N-YS	NETERZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\udmlEPTB;MUi1JI5O	NHThe2NUSU6JRWK=
J82	NFfqWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTF6NT6xPEBvVQ>?	MUHTRW5ITVJ?
LS-411N	M4rYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF6Nz6yPEBvVQ>?	NHm2NZdUSU6JRWK=
HCC1937	MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLGUo5sUUN3ME2xPFcvPDlibl2=	M2i5cXNCVkeHUh?=
OE33	NGLpUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHBWIw2UUN3ME2xPFgvQTdibl2=	NED2O3hUSU6JRWK=
NB7	NV;QOpZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnOU2k1UUN3ME2xPFkvQDlibl2=	NWXYPYJ2W0GQR1XS
SW684	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7id29zUUN3ME2xPVYvOTNibl2=	MofDV2FPT0WU
HT-144	NV;nN2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LvSGlEPTB;MUm2MlE2KG6P	M13vW3NCVkeHUh?=
SK-MEL-30	M3TONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nDXWlEPTB;MUm2MlIhdk1?	NF;5fIlUSU6JRWK=
DBTRG-05MG	NFPTeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7mTWM2OD1zOUiuOFchdk1?	M2jjWXNCVkeHUh?=
NCI-H1395	M3vnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF7OD64OUBvVQ>?	NIjpfYpUSU6JRWK=
NCI-H2122	MmHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJyMD61PUBvVQ>?	M4DQ[HNCVkeHUh?=
no-10	NEi3dW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn5dGdKSzVyPUKwNU4xPCCwTR?=	NEfHSYNUSU6JRWK=
SW48	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofxTWM2OD1{MEGuN\|Ehdk1?	MWjTRW5ITVJ?
NCI-H1650	NFnGNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW[ydGprUUN3ME2yNFQvODFibl2=	NXrMU5JbW0GQR1XS
MZ1-PC	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTJyNT61PEBvVQ>?	NXzMSnBDW0GQR1XS
U-266	NVXrbFRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jU[mlEPTB;MkC1Mlc6KG6P	NV;4PHBKW0GQR1XS
CAS-1	M3j1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITJbG9KSzVyPUKwO{41PCCwTR?=	NGXKW2hUSU6JRWK=
AU565	M3jKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJzMj64NkBvVQ>?	Mn[wV2FPT0WU
UACC-257	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4riZ2lEPTB;MkGzMlk6KG6P	NULjbGdKW0GQR1XS
CAL-27	NGHzOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHNTWM2OD1{MUeuNFUhdk1?	M{jmRXNCVkeHUh?=
NCI-H23	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVX6UHhHUUN3ME2yNVkvOzNibl2=	MVzTRW5ITVJ?
TE-6	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLuTWM2OD1{MUmuOlghdk1?	NU\sVZhDW0GQR1XS
TGBC24TKB	NF[ySoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrwbINKSzVyPUKyNk4yPyCwTR?=	NX\HW3k4W0GQR1XS
TE-1	NXvYPJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4frRmlEPTB;MkKyMlg5KG6P	NGnvboVUSU6JRWK=
RCC10RGB	NXTsTmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn4UW1KSzVyPUKyOE4yQSCwTR?=	NXTmT2tTW0GQR1XS
NCI-H596	NUPybXdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\4[WhKSzVyPUKyPE4zOiCwTR?=	MWXTRW5ITVJ?
SW954	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHuWlhIUUN3ME2yN\|MvQDNibl2=	NX\GNHJ2W0GQR1XS
NCI-H2087	MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3XZ3czUUN3ME2yN\|QvPTFibl2=	NYHaOmRLW0GQR1XS
SK-PN-DW	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrxcIdpUUN3ME2yN\|UvOTlibl2=	NE\BPW5USU6JRWK=
KM12	M1HZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGriWlJKSzVyPUKzOU44KG6P	NXzNfVlmW0GQR1XS
BT-474	NXS1W2lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1m0UmlEPTB;MkO1Mlc{KG6P	M1LnfHNCVkeHUh?=
IST-MES1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XNXGlEPTB;MkO2MlU4KG6P	Mor2V2FPT0WU
HT-1197	M3\XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTWTWM2OD1{M{iuNFkhdk1?	MWLTRW5ITVJ?
CAL-54	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJ\|OD60PUBvVQ>?	NHzhPZZUSU6JRWK=
NB10	M1\4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfWVGhRUUN3ME2yOFAvODZibl2=	Mn\CV2FPT0WU
PANC-10-05	NUTvS4dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfUfnVKSzVyPUK0OU42PiCwTR?=	NYTBUFRFW0GQR1XS
NCI-H522	M1LQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{XvVWlEPTB;MkS4MlMyKG6P	M1:zd3NCVkeHUh?=
A388	M2\NUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXPGNlYyUUN3ME2yOFkvQDJibl2=	MlTrV2FPT0WU
GOTO	M3\VUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJ3MD6yPUBvVQ>?	MUPTRW5ITVJ?
KLE	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrVeXZ2UUN3ME2yOVEvQDdibl2=	MoWxV2FPT0WU
KYSE-520	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\mUWlEPTB;MkWyMlg3KG6P	NGLm[5FUSU6JRWK=
HCE-4	M4\uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4i5cGlEPTB;Mk[yMlUhdk1?	MULTRW5ITVJ?
KURAMOCHI	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTW[YpKSzVyPUK2OU46KG6P	Moi4V2FPT0WU
HCC38	NVHrWVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTFOotKSzVyPUK2Ok41QCCwTR?=	NVfkblBWW0GQR1XS
FADU	NHvIcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\OVFdKSzVyPUK2Ok43OyCwTR?=	NEDhSWZUSU6JRWK=
CW-2	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7MNGVKSzVyPUK2PU46PiCwTR?=	M3vTdnNCVkeHUh?=
L-428	M4DqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nOZWlEPTB;Mke1MlE2KG6P	NUXJN2RqW0GQR1XS
HCC1569	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjmTWM2OD1{N{WuPFQhdk1?	Mny3V2FPT0WU
NCI-H810	NF\ISXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXiTWM2OD1{N{iuN\|Ehdk1?	MkTzV2FPT0WU
LB771-HNC	Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfKVXJqUUN3ME2yPFUvQDRibl2=	NH:2OoNUSU6JRWK=
LCLC-103H	NWXCVIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLITWM2OD1{OEWuPVkhdk1?	MYXTRW5ITVJ?
EFO-21	M4K0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;qO2pKSzVyPUK4O{43QCCwTR?=	NFT3bFBUSU6JRWK=
CAL-72	NXjsO45nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LMSGlEPTB;MkmzMlE6KG6P	MUTTRW5ITVJ?
SCC-9	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjXR49KSzVyPUK5N{4zOiCwTR?=	M4DqSXNCVkeHUh?=
COLO-829	M1jG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPhR5RXUUN3ME2yPVYvPSCwTR?=	NYDudGt5W0GQR1XS
U-87-MG	M4Hjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvOTWM2OD1\|MECuO\|Mhdk1?	M4fZSXNCVkeHUh?=
MZ7-mel	M2X6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n3NGlEPTB;M{KzMlc3KG6P	MX\TRW5ITVJ?
NCI-H1770	NVP3epQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1r6T2lEPTB;M{K2Mlc1KG6P	NV\TcI5tW0GQR1XS
ChaGo-K-1	NHfqbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrzTWM2OD1\|MkiuNUBvVQ>?	M{jRe3NCVkeHUh?=
SiHa	Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzvPI1KSzVyPUOyPU4zPCCwTR?=	MXPTRW5ITVJ?
NCI-SNU-5	MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3VTWM2OD1\|M{[uO\|chdk1?	MVjTRW5ITVJ?
DJM-1	M4PNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTN2MD6zN{BvVQ>?	NVrHcpB6W0GQR1XS
OE19	NH\xe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfOZ4V5UUN3ME2zOFAvPTNibl2=	MVLTRW5ITVJ?
NCI-H1651	NUmwb2ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPndnVKSzVyPUO0OE4yQCCwTR?=	MWTTRW5ITVJ?
COLO-792	NWPQNGRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3zTWM2OD1\|NUSuOFIhdk1?	M{W5WXNCVkeHUh?=
ACHN	NXO4[nhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDxTWM2OD1\|NU[uO\|Ehdk1?	NUX6WGsxW0GQR1XS
TH-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYP0V5h4UUN3ME2zO\|kvQTVibl2=	MkjmV2FPT0WU
HT-1376	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfiTWM2OD1\|OESuPFghdk1?	M3;4fXNCVkeHUh?=
RH-18	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTN7ND63OEBvVQ>?	NELETZhUSU6JRWK=
NB6	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfuTXg1UUN3ME2zPVYvPjZibl2=	NX\wUFB4W0GQR1XS
COLO-320-HSR	NF\u[\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFOzTXRKSzVyPUSwN{4{PyCwTR?=	M{OzZnNCVkeHUh?=
UACC-893	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTRyNj60O{BvVQ>?	MlrwV2FPT0WU
DSH1	NEf2eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPk[lRQUUN3ME20NFYvQTFibl2=	M2DHS3NCVkeHUh?=
TE-10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3YTXlKSzVyPUSwO{4xOSCwTR?=	M{jkWXNCVkeHUh?=
HCC70	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnCUVdKSzVyPUSwPU4zOSCwTR?=	NVPLXXBrW0GQR1XS
TGBC11TKB	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInFT2xKSzVyPUSxNE4{OyCwTR?=	M17CVXNCVkeHUh?=
NCI-H727	NVu5cndvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\GTWM2OD12MUKuNVEhdk1?	NYTUeY9[W0GQR1XS
ALL-PO	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknqTWM2OD12MUWuOlkhdk1?	MXzTRW5ITVJ?
ABC-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlX3TWM2OD12MkCuOFUhdk1?	NX7KVodwW0GQR1XS
NCI-H69	NUf5VJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLy[XRKSzVyPUSyOk44PiCwTR?=	NYr4W3hJW0GQR1XS
GP5d	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPoOVJyUUN3ME20N\|QvPDFibl2=	NFH5VoNUSU6JRWK=
UMC-11	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTR3OD6zOkBvVQ>?	NFrnT2VUSU6JRWK=
RMG-I	M3n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWexO4l[UUN3ME20OlcvPTZibl2=	M3;kfHNCVkeHUh?=
YAPC	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfvTpFSUUN3ME20PVAvPiCwTR?=	Ml:1V2FPT0WU
LS-1034	NIfDdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr4OYpyUUN3ME20PVEvODZibl2=	NWnnTIxKW0GQR1XS
RCM-1	M3LBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTR7Nj62PEBvVQ>?	MXrTRW5ITVJ?
HCC1954	M4fp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jsdmlEPTB;NUGyMlUhdk1?	MV;TRW5ITVJ?
SK-MEL-24	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\6SYIzUUN3ME21NVYvPTFibl2=	Mlf2V2FPT0WU
NB12	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr4TWM2OD13MkiuOFIhdk1?	NWjZR2lSW0GQR1XS
SW756	NWi5UlQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTZd5lKSzVyPUW1OE46PiCwTR?=	M{THWHNCVkeHUh?=
HCC1187	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIqxPXBKSzVyPUW3OU45OyCwTR?=	NYPCcnV4W0GQR1XS
NCI-H2342	M13CNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkC3TWM2OD13OUCuN\|khdk1?	MnzwV2FPT0WU
NCI-H2291	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXRN3JKSzVyPUW5PE4{OSCwTR?=	M2\YeXNCVkeHUh?=
OVCAR-3	NF[4R4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTVTWM2OD13OUiuPVYhdk1?	NYe5O3lPW0GQR1XS
MHH-NB-11	NYHGb5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLETWM2OD14MkmuNFEhdk1?	MnrjV2FPT0WU
SAS	M33D[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PXOGlEPTB;NkWyMlY4KG6P	NFnDVVhUSU6JRWK=
COLO-824	MoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHkflJJUUN3ME22PFkvOzdibl2=	NWjleGVWW0GQR1XS
HCC1395	M2jsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXIW4c2UUN3ME22PVgvPSCwTR?=	Mn30V2FPT0WU
COLO-668	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LXWWlEPTB;N{C2MlEhdk1?	MXTTRW5ITVJ?
NCI-H226	MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHXfHI1UUN3ME23NFcvQCCwTR?=	MXfTRW5ITVJ?
NB17	NEDpUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTd{MT63OUBvVQ>?	MnriV2FPT0WU
SW1463	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIr0VZZKSzVyPUezPU4yQSCwTR?=	MnG0V2FPT0WU
TGW	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTd4MD6xOUBvVQ>?	MkHCV2FPT0WU
NCI-H526	NY\zRmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2S0PGlEPTB;OEKzMlU{KG6P	MmLsV2FPT0WU
COR-L88	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NET2O5dKSzVyPUi0PE4yOiCwTR?=	M37xO3NCVkeHUh?=
NCI-H441	NHLIXI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX3TWM2OD16OUWuNlIhdk1?	NEHNXJlUSU6JRWK=
NCI-H630	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHaTWM2OD17MUKuPVYhdk1?	MkGyV2FPT0WU
Mo-T	NG\KWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLKTWM2OD17NEeuPFghdk1?	M{TMNnNCVkeHUh?=
JAR	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn0SnlwUUN3ME25OVYvOjRibl2=	NHP6U3VUSU6JRWK=
NCI-H1838	Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fmOGlEPTB;MT6wNlM5QCEQvF2=	NUXaV3hSW0GQR1XS
DoTc2-4510	M1q3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfWR\|JKSzVyPUGuNFc{PzZizszN	MoPnV2FPT0WU
MKN28	NVXO[3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\v[YNKSzVyPUGuNFkxOjRizszN	NXvLbm85W0GQR1XS
HuP-T3	NVzpeVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7nTWM2OD1zLkGxPVA2KM7:TR?=	NIjYcIhUSU6JRWK=
TE-9	NF\meG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFwMUK5O\|Mh\|ryP	MWPTRW5ITVJ?
NY	M1v0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPnS5VKSzVyPUGuNVY4QTJizszN	M133NXNCVkeHUh?=
HT55	M4XYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwM{GzOFQh\|ryP	M3r2PHNCVkeHUh?=
SW837	NXvTRWpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVqzOVdpUUN3ME2xMlMzQTd6IN88US=>	NHLuOJdUSU6JRWK=
NCI-H2029	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTFwNEG3PVEh\|ryP	NVjVWlBGW0GQR1XS
IST-SL1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwNESyOEDPxE1?	M3LvdHNCVkeHUh?=
COLO-741	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEGwUXZKSzVyPUGuOFk4PzFizszN	M{m2PXNCVkeHUh?=
LU-65	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvp[2NKSzVyPUGuOlIzPDlizszN	NFLiXnpUSU6JRWK=
NCI-H1304	NHvPVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPQTWM2OD1zLk[1OFk5KM7:TR?=	NX7F[IZGW0GQR1XS
KARPAS-299	NIHST\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP5TWM2OD1zLke5OFc6KM7:TR?=	NFPnWGNUSU6JRWK=
NCI-H358	NIjzPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYmz[FJNUUN3ME2xMlk2PTB\|IN88US=>	MmjRV2FPT0WU
OAW-28	NYP5S5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXq4UIcyUUN3ME2yMlA3QTF7IN88US=>	NWDyUIFbW0GQR1XS
C8166	NEiwdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfnfZpTUUN3ME2yMlY{Ozl{IN88US=>	MX7TRW5ITVJ?
COLO-678	NUfGTXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Xxc2lEPTB;Mj64N\|c3QCEQvF2=	MknOV2FPT0WU
SK-N-DZ	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXlVnVKSzVyPUKuPFY{QDFizszN	MWPTRW5ITVJ?
NCI-H82	NEnN[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NImzbXBKSzVyPUKuPVA{PjlizszN	MYfTRW5ITVJ?
JVM-2	Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrvTWM2OD1\|LkCzNVg5KM7:TR?=	M{\qTXNCVkeHUh?=
SW1116	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTNwMEW0NVEh\|ryP	MmfyV2FPT0WU
MDA-MB-453	NF76TZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULQU\|NQUUN3ME2zMlExPDN7IN88US=>	M{iyRXNCVkeHUh?=
Calu-6	M4\4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoT1TWM2OD1\|LkG5PVch\|ryP	MnjZV2FPT0WU
SHP-77	NYrSflFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\2TWM2OD1\|LkWyPEDPxE1?	M4e5TXNCVkeHUh?=
Capan-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2[wNWlEPTB;ND6zNlU5OSEQvF2=	NGXHXYFUSU6JRWK=
SW948	NFu1NVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTRwN{S3O\|kh\|ryP	M2W5WXNCVkeHUh?=
HDLM-2	MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PXSWlEPTB;NT6wO\|czPSEQvF2=	NUjadZVOW0GQR1XS
LAN-6	MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\RUGlEPTB;Nj6yNVQ6PSEQvF2=	MVzTRW5ITVJ?
LU-135	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HOSGlEPTB;Nj60N\|A4PyEQvF2=	MlrIV2FPT0WU
T84	NVi3NnlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIL4Z\|lKSzVyPU[uPVg3PCEQvF2=	Ml;aV2FPT0WU
CAPAN-1	M335[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXLTYRKSzVyPUeuOlIzOzNizszN	NUThW4p4W0GQR1XS
SW1417	NIDsdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjZW21TUUN3ME23MlkyPzNzIN88US=>	M1rzUHNCVkeHUh?=
BALL-1	NVjhc49iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PBd2lEPTB;OD61NFQxQSEQvF2=	MWPTRW5ITVJ?
HT-29	M4DFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknvTWM2OD17LkC3OVk6KM7:TR?=	MULTRW5ITVJ?
C3A	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnGTWM2OD17Lki4N\|k1KM7:TR?=	NFjGS5ZUSU6JRWK=
NCI-H1993	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f1[WlEPTB;MUCuOVA5OSEQvF2=	MWDTRW5ITVJ?
SK-MEL-1	NImyWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTFzLk[yPFkh\|ryP	M1nXTHNCVkeHUh?=
DU-145	M2ThVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{S0VGlEPTB;MUSuOVA2OiEQvF2=	NF[1[2dUSU6JRWK=
KP-N-YN	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrGTWM2OD1zND61NVA{KM7:TR?=	NH\qfWFUSU6JRWK=
CCRF-CEM	NIDsZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;3PJVKSzVyPUG0Mlc5ODlizszN	MlOyV2FPT0WU
ZR-75-30	MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF4LkOzNFMh\|ryP	NGP6dppUSU6JRWK=
A673	M{TlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TL[2lEPTB;MkCuOVUxPyEQvF2=	NYXXfHhCW0GQR1XS
K-562	NWDERmlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljGTWM2OD1{OD60NVg{KM7:TR?=	NWXMXVJ5W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Formulation: NMP/polyethylene glycol 300 (10/90, v/v) Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NVP-BEZ235

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01482156	Completed	Drug: RAD001 + BEZ235	Advanced Solid Tumors\|Metastatic Breast Cancer\|Metastatic Renal Cell Carcinoma	Novartis Pharmaceuticals\|Novartis	January 2012	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)